Egyptian Board Gastroenterology & Hepatology common mistakes
Egyptian Board Gastroenterology & Hepatology · Understand the traps and how to avoid them.
When a cirrhosis case presents with ascites, the candidate calculates the SAAG, obtains a value ≥1.1 g/dL, and then stops - declaring 'portal hypertension' and moving on without applying the full serum-ascites albumin gradient plus ascitic fluid total protein algorithm to separate cardiac ascites, Budd-Chiari, and peritoneal TB/carcinomatosis.
SAAG is taught early and reinforced as 'the' ascites test, so it becomes a terminal answer rather than an intermediate step. High-yield summaries rarely show the second branch (high SAAG with high ascitic protein points to cardiac or post-sinusoidal causes), so candidates never rehearse it. Time pressure during case vignettes rewards the first satisfying diagnostic label.
What to do instead
Before answering any ascites question, write a two-by-two grid on scratch paper: SAAG <1.1 vs ≥1.1 across the top, ascitic total protein low vs high down the side. Fill all four cells with the differential before selecting an option. Specifically drill the high-SAAG/high-protein cell (cardiac failure, constrictive pericarditis, Budd-Chiari, sinusoidal obstruction syndrome) and the low-SAAG cell (peritoneal TB, carcinomatosis, pancreatic ascites, serositis). Add ascitic fluid ADA, LDH, and cytology to your mental checklist whenever the stem mentions fever, weight loss, or a travel/immigration history.
In a lower GI bleeding vignette, the candidate immediately selects 'urgent colonoscopy' or 'tagged RBC scan' for a hemodynamically unstable patient with massive hematochezia, skipping the step of upper endoscopy to exclude a brisk upper GI source and skipping resuscitation/risk stratification before any test.
Hematochezia is intuitively linked to the colon, and colonoscopy is the familiar test. Candidates also conflate 'the best test to find the bleeding site' with 'the first thing to do', forgetting that airway, access, transfusion thresholds, and reversal of anticoagulation precede localization. Massive upper GI bleeds can present as hematochezia when transit is fast.
What to do instead
Adopt a fixed sequence for every GI bleed stem: (1) resuscitate and risk-stratify (Glasgow-Blatchford, Rockall), (2) decide upper vs lower probability - if the patient is unstable with hematochezia, upper endoscopy comes first because a bleeding duodenal ulcer is far more common than a massive colonic source, (3) only then choose localization (CT angiography for active massive bleeding, colonoscopy after bowel prep for stable patients, capsule or push enteroscopy for obscure bleeding). Practice by sorting ten bleeding vignettes into 'unstable' vs 'stable' and 'upper-likely' vs 'lower-likely' before looking at answer choices.
The candidate diagnoses irritable bowel syndrome in a patient with alarm features (iron-deficiency anemia, unintentional weight loss, nocturnal symptoms, family history of colorectal cancer, age over 45 with new symptoms) purely because the Rome criteria are met, and does not select colonoscopy or celiac serology as the next step.
Rome criteria are memorized as a checklist and applied mechanically; the exclusion of organic disease is treated as a footnote rather than part of the definition. Candidates also under-weight iron-deficiency anemia in men and postmenopausal women as a mandatory colonoscopy trigger.
What to do instead
When a stem lists Rome criteria, immediately scan the same stem for alarm features and make a two-column list: 'supports IBS' vs 'red flags present'. If any red flag exists, the correct answer is the investigation that excludes organic disease (colonoscopy for anemia/bleeding/age, celiac serology for bloating/diarrhea/weight loss, fecal calprotectin to separate IBS from IBD). Memorize the specific red-flag list rather than the general phrase 'alarm features'.
On H. pylori questions the candidate picks eradication therapy without checking prior macrolide or clarithromycin exposure, local clarithromycin resistance rates, or penicillin allergy, and then fails to specify a confirmatory test timed at least four weeks after therapy and off proton-pump inhibitors for two weeks.
The classic triple therapy (PPI + clarithromycin + amoxicillin) is overlearned as 'the' answer. Guideline shifts toward bismuth quadruple therapy in high-resistance or previously macrolide-exposed patients are newer and less rehearsed. The test-of-cure timing rule (stop PPI 2 weeks, stop antibiotics/bismuth 4 weeks before testing) is a detail candidates read once and forget.
What to do instead
For every H. pylori question, run a three-question filter before choosing: (1) Has the patient had prior clarithromycin/macrolide exposure or is local resistance >15%? If yes, bismuth quadruple or non-clarithromycin regimen. (2) Penicillin allergy? Then avoid amoxicillin-based triple. (3) How will cure be confirmed? Use urea breath test or stool antigen - never serology - at ≥4 weeks post-therapy with PPI held 2 weeks. Write these three filters on a single card and apply them to every H. pylori stem, including those framed as 'which regimen is most appropriate'.
The candidate interprets a positive anti-tissue transglutaminase IgA as diagnostic of celiac disease and proceeds to a gluten-free diet, without checking total serum IgA (to exclude selective IgA deficiency, where tTG-IgA is falsely negative) and without confirming the need for duodenal biopsies while still on a gluten-containing diet.
Serology is taught as highly sensitive and specific, so the confirmatory biopsy step feels redundant. The IgA deficiency caveat and the 'do not start the diet before biopsy' rule are small print that candidates skip. In older adults, celiac is under-suspected, so the stem's anemia or osteoporosis is attributed elsewhere.
What to do instead
Build a celiac algorithm: step 1, order total IgA with tTG-IgA (if IgA deficient, use IgG-based tests such as tTG-IgG or deamidated gliadin IgG); step 2, if serology positive, refer for upper endoscopy with at least four duodenal biopsies including the bulb, while the patient remains on gluten; step 3, only a biopsy showing villous atrophy with intraepithelial lymphocytosis confirms the diagnosis in adults. Note the exception where guidelines permit no-biopsy diagnosis in children with very high titers. Apply this sequence to any stem with iron-deficiency anemia, chronic diarrhea, weight loss, or metabolic bone disease.
In acute pancreatitis the candidate focuses on lipase levels and imaging but fails to classify severity using the revised Atlanta criteria (persistent organ failure >48 hours defines severe disease), misses the timing rule that CT for necrosis is unhelpful before about 72 hours, and does not address early fluid resuscitation, enteral (not parenteral) nutrition, or ERCP timing for gallstone pancreatitis with cholangitis.
Pancreatitis is taught as 'lipase plus pain', and severity scoring is perceived as academic. The revised Atlanta classification replaced older Ranson/APACHE framing in many curricula, and candidates mix the two. The 'early CT shows nothing' and 'feed enterally, not parenterally' rules are management details that get crowded out.
What to do instead
For each pancreatitis stem, answer four fixed questions: (1) Are there transient (<48 h) or persistent (>48 h) organ failures? Persistent = severe. (2) Is there cholangitis or persistent biliary obstruction? If yes, urgent ERCP within 24–48 h; if no, ERCP is not indicated early. (3) Is there a role for CT now? Only if the diagnosis is unclear or after ~72 h to assess necrosis. (4) How is the patient fed? Enteral nutrition early; parenteral only if enteral is not tolerated. Also remember antibiotics are not given prophylactically for sterile necrosis.
The candidate manages an upper GI bleed by transfusing to a normal hemoglobin, giving IV PPIs and then discharging after hemostasis without addressing the post-hemostasis H. pylori test-and-treat, NSAID discontinuation, or the decision on when to restart antiplatelets/anticoagulants - and misstates the restrictive transfusion threshold.
The acute endoscopic moment dominates attention, so the equally tested secondary-prevention and drug-restart decisions are neglected. Transfusion thresholds are a moving target and candidates default to 'correct the number'. The restart timing of antiplatelet therapy after peptic ulcer bleeding is a frequently examined but rarely rehearsed nuance.
What to do instead
After choosing endoscopic hemostasis, force yourself to answer three follow-on questions in the same stem: (1) Transfusion threshold - restrictive strategy (typically hemoglobin ~7 g/dL, higher in massive exsanguination or ischemic heart disease). (2) H. pylori - test and eradicate, since eradication prevents rebleeding. (3) Drugs - stop NSAIDs; in patients on antiplatelets for secondary cardiovascular prevention, restart aspirin early (generally within days) after hemostasis rather than withholding for weeks. Practice by taking any bleeding-ulcer stem and writing the discharge plan, not just the endoscopic plan.
When a stem describes a patient with cirrhosis and fever or altered mentation, the candidate orders a diagnostic paracentesis but interprets a polymorphonuclear cell count threshold incorrectly (using >500 instead of ≥250 cells/mm³), omits ascitic fluid culture in blood-culture bottles, and fails to start empirical third-generation cephalosporin plus albumin for spontaneous bacterial peritonitis.
The PMN cutoff is a single number that is easy to misremember, and candidates confuse it with the protein or SAAG thresholds. The albumin adjunct (typically 1.5 g/kg on day 1 and 1 g/kg on day 3) to reduce hepatorenal syndrome is a detail that is tested but rarely drilled. Fever in cirrhosis is also misattributed to pneumonia or UTI without ruling out SBP.
What to do instead
Memorize a single SBP bundle: diagnostic paracentesis in every cirrhotic inpatient with ascites at admission, PMN ≥250 cells/mm³ is diagnostic, inoculate ascitic fluid into blood-culture bottles at the bedside, and treat with IV cefotaxime (or similar third-generation cephalosporin) plus IV albumin 1.5 g/kg day 1 and 1 g/kg day 3, especially with renal impairment. Also note secondary peritonitis clues (multiple organisms, very high protein, low glucose) and remember prophylaxis indications (prior SBP, low-protein ascites with renal/hepatic failure).
On endoscopy and GI oncology questions the candidate recommends surveillance intervals or screening tests without matching them to the patient's risk category - for example applying a 10-year colonoscopy interval to a patient with a strong family history or prior advanced adenoma, or choosing the wrong post-polypectomy interval based on polyp size, number, and histology.
Screening intervals are numerous and context-dependent, and candidates memorize one 'default' interval. Post-polypectomy surveillance guidelines are organized by risk group, which requires reading the polyp details in the stem rather than pattern-matching to 'colonoscopy in 10 years'.
What to do instead
Create a risk-stratification table: average risk (start screening at 45–50, options include colonoscopy every 10 years or stool-based testing annually/every 3 years), family history of CRC or advanced adenoma (start earlier, often 10 years before the youngest case, and repeat more frequently), and post-polypectomy groups (low-risk vs high-risk based on number, size ≥10 mm, villous histology, and dysplasia). For each practice stem, first classify the patient into a risk group, then select the interval. Do the same for Barrett's esophagus surveillance and for gastric intestinal metaplasia where applicable.
The candidate answers an evidence-based-practice or ethics item by choosing the most clinically aggressive option - for example selecting a screening test with high sensitivity but very low specificity without discussing lead-time and length-time bias, or overriding a competent patient's refusal of a life-saving procedure 'because the physician knows best'.
Clinical training rewards action, and candidates carry that bias into methodology and ethics questions. Screening biases (lead-time, length-time, overdiagnosis) are abstract and rarely rehearsed. Ethical principles are memorized as labels but not applied to the specific question of decisional capacity and informed refusal. Research-methodology items on study design, intention-to-treat, and confounding are also under-practiced.
What to do instead
For methodology stems, name the bias explicitly before choosing: lead-time bias inflates survival without changing mortality, length-time bias favors detection of slow-growing disease, and overdiagnosis inflates incidence without benefit - the correct screening endpoint is disease-specific mortality in a randomized trial, not survival. For ethics stems, run a capacity check: does the patient understand, appreciate, reason, and express a choice? If capacity is intact, informed refusal is respected even if the outcome is poor; involve family only with consent. For therapy questions, prefer the option supported by patient-important outcomes (mortality, morbidity) over surrogate endpoints.